Abstract
Introduction: The focus on cost-containment imposed by shrinking national health care budgets is increasingly putting pressure on investigators to demonstrate that newer interventions are not only effective but also cost-effective. In the area of assisted reproductive technology (ART) a shift in usage is occurring from urinary derived to biotechnology – derived (recombinant) gonadotropins for ovarian stimulation. Provision of treatment with ART often involves several cycles of treatment, each associated with multiple steps with varying outcomes at each step. To take into account all the situations that are possible during the repeated cycles of treatment when trying to evaluate different ovarian stimulation regimens is a complex task that requires large numbers of subjects to adequately address the cost-effectiveness of these therapies. A more efficient approach is to employ modeling techniques that can easily be applied to the different national health care systems. The objective of this study was to compare the cost-effectiveness of rec ombinant(r) FSH with urinary(u) FSH in the UK, USA, Germany and Spain.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
